文献速递类风湿关节炎

Fostamatinib治疗MTX应答不佳的亚洲类风湿关节炎患者的II期研究

Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

两项II期研究评估了fostamatinib在甲氨蝶呤(MTX)治疗下仍活动的大亚洲类风湿关节炎(RA)患者中的疗效与长期安全性。OSKIRA-Asia-1为12周双盲安慰剂对照研究,OSKIRA-Asia-1X为长期扩展研究。结果显示fostamatinib在部分剂量组达到ACR20/50/70及低疾病活动度的统计学显著改善,安全性与既往研究一致。

要点

  • Fostamatinib在部分剂量组对MTX应答不佳的亚洲RA患者显示ACR20/50/70的统计学显著改善。
  • 常见不良事件包括高血压、腹泻和中性粒细胞减少。
  • 长期扩展研究安全性与既往研究一致。

核心结论

  • Fostamatinib在RA体征和症状方面取得了统计学和临床显著的改善。
  • Fostamatinib(联合MTX)的安全性和耐受性与既往研究一致。

研究设计与样本

  • OSKIRA-Asia-1为12周、多中心、双盲、安慰剂对照、平行组研究,患者随机接受四种fostamatinib剂量之一(A-D组,n=31、33、33、33)或安慰剂(E组,n=33)。
  • OSKIRA-Asia-1X为长期扩展研究,纳入完成OSKIRA-Asia-1的患者,接受fostamatinib 100 mg每日一次。

主要发现

  • 在第12周,A组(100 mg每日两次)和B组(100 mg每日两次,后改为150 mg每日一次)的ACR20应答较安慰剂有数值上的改善。
  • A组和B组在第8周ACR20和ACR50、第12周ACR70以及基于C反应蛋白的28关节计数DAS≤3.2的低疾病活动度方面达到统计学显著改善。
  • A组身体功能改善在数值上更高。
  • OSKIRA-Asia-1中最常见的不良事件为高血压、腹泻和中性粒细胞减少;OSKIRA-Asia-1X中最常见的不良事件为鼻咽炎、高血压、RA和中性粒细胞减少。

关键数值与推荐

  • 低疾病活动度定义为基于C反应蛋白的28关节计数DAS≤3.2。
  • 疗效通过ACR应答标准和基于28关节计数的DAS评估。
  • 身体功能状态通过HAQ残疾指数评估。

临床怎么用

  • 对于MTX应答不佳的亚洲RA患者,fostamatinib联合MTX可能改善疾病活动度和身体功能。
  • 使用fostamatinib时应监测高血压、腹泻和中性粒细胞减少等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The primary objectives of two phase II studies of fostamatinib were to evaluate efficacy (OSKIRA-Asia-1: NCT01569074) and long-term safety/tolerability (OSKIRA-Asia-1X: NCT01640054) in patients from Asia with active RA despite MTX treatment. METHODS: OSKIRA-Asia-1 was a 12-week, multicentre, double-blind, placebo-controlled, parallel-group study. Patients were randomized to receive one of four fostamatinib doses (groups A-D; n = 31, 33, 33, 33) or placebo (group E; n = 33). OSKIRA-Asia-1X was a long-term extension study (100 mg fostamatinib qd) of patients who completed OSKIRA-Asia-1. RA signs and symptoms were measured by ACR response criteria and DAS based on a 28-joint count. Physical function status was assessed with the HAQ-Disability Index. Safety findings were monitored. RESULTS: In OSKIRA-Asia-1, fostamatinib revealed numerical improvements in ACR 20% response (ACR20) at week 12 in group A (100 mg bid) and group B (100 mg bid, then 150 mg qd) vs placebo. Statistically significant improvements in ACR20 and ACR50 at week 8 and in ACR70 at week 12, and statistically significant achievement in low disease activity (defined as DAS based on a 28-joint count ≤3.2 based on C-reactive protein) occurred in groups A and B. Improvement in physical function was numerically higher in group A. The most common adverse events were hypertension, diarrhoea and neutropenia. In OSKIRA-Asia-1X, the most common adverse events were nasopharyngitis, hypertension, RA and neutropenia. CONCLUSION: Fostamatinib achieved both statistically and clinically significant improvements in RA signs and symptoms. The safety and tolerability of fostamatinib (plus MTX) were consistent with previous studies. TRIAL REGISTRATION: OSKIRA-Asia-1 trial registration: https://clinicaltrials.gov, NCT01569074; OSKIRA-Asia-1X trial registration: https://clinicaltrials.gov, NCT01640054.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Tanaka Y, Millson D, Iwata S, et al. Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. Rheumatology (Oxford). 2021. PMID: 33254235. doi:10.1093/rheumatology/keaa732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。